Changes in Insulin-like Growth Factor-1 Level in Patients with Sepsis and Septic Shock
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Despite many ongoing, prospective studies on the topic, sepsis still remains one of the main causes of death in hospital. The hormone insulin-like growth factor 1 (IGF-1) has a similar molecular structure to that of insulin. IGF-1 exerts anabolic effects and plays important roles in both normal physiology and pathologic processes. Previous studies have observed low serum IGF-1 level in patients with critical illnesses. Here, we evaluated changes in IGF-1 level based on survival of septic patients. Methods: We evaluated 140 patients with sepsis and septic shock (21 with sepsis and 119 with septic shock) admitted to the intensive care unit of a university-affiliated hospital in Korea. Serum IGF-1 level was measured on days 0, 1, 3, and 7. Patients with liver disease were excluded from this study. All data were analyzed using SPSS version 20 (SPSS Inc., Chicago, IL, USA). Results: Patients with septic shock had significantly lower serum IGF-1 level on days 1 and 3 than patients without septic shock (p = 0.002 and p = 0.007, respectively). Generally, there was a negative relationship between IGF-1 and serum cortisol levels; however, this relationship was only significant on day 3 (p = 0.029). Furthermore, renin showed significantly negative correlation with IGF-1 on day 3 (p = 0.038). IGF-1 level did not show significant difference between survivors and non-survivors. Conclusions: Our results showed that IGF-1 was associated with septic shock, and that the IGF-1 axis is severely disrupted in septic patients. Additionally, serum cortisol and renin levels were associated with IGF-1 level.
Abstract
Background: Despite many ongoing, prospective studies on the topic, sepsis still remains one of the main causes of death in hospital. The hormone insulin-like growth factor 1 (IGF-1) has a similar molecular structure to that of insulin. IGF-1 exerts anabolic effects and plays important roles in both normal physiology and pathologic processes. Previous studies have observed low serum IGF-1 level in patients with critical illnesses. Here, we evaluated changes in IGF-1 level based on survival of septic patients. Methods: We evaluated 140 patients with sepsis and septic shock (21 with sepsis and 119 with septic shock) admitted to the intensive care unit of a university-affiliated hospital in Korea. Serum IGF-1 level was measured on days 0, 1, 3, and 7. Patients with liver disease were excluded from this study. All data were analyzed using SPSS version 20 (SPSS Inc., Chicago, IL, USA). Results: Patients with septic shock had significantly lower serum IGF-1 level on days 1 and 3 than patients without septic shock (p = 0.002 and p = 0.007, respectively). Generally, there was a negative relationship between IGF-1 and serum cortisol levels; however, this relationship was only significant on day 3 (p = 0.029). Furthermore, renin showed significantly negative correlation with IGF-1 on day 3 (p = 0.038). IGF-1 level did not show significant difference between survivors and non-survivors. Conclusions: Our results showed that IGF-1 was associated with septic shock, and that the IGF-1 axis is severely disrupted in septic patients. Additionally, serum cortisol and renin levels were associated with IGF-1 level.
참고문헌 (33)
- Assuncao MS, "The cost-effectiveness ratio of a managed protocol for severe sepsis", J Crit Care, 29(692), pp.e1~e6 (2014)
- Mouncey PR, "Trial of early, goaldirected resuscitation for septic shock", N Engl J Med, 372, pp.1301~1311 (2015)
- ARISE Investigators, "Goal-directed resuscitation for patients with early septic shock", N Engl J Med, 371, pp.1496~1506 (2014)
- ProCESS Investigators, "A randomized trial of protocol-based care for early septic shock", N Engl J Med, 370, pp.1683~1693 (2014)
- Russell JA, "Management of sepsis", N Engl J Med, 355, pp.1699~1713 (2006)
- Vincent JL, "Assessment of the worldwide burden of critical illness:the intensive care over nations (ICON) audit", Lancet Respir Med, 2, pp.380~386 (2014)
- Zhang Q, "Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department", Intensive Care Med, 40, pp.1499~1508 (2014)
- Bondanelli M, "Systemic illness", Pituitary, 11, pp.187~207 (2008)
- Papastathi C, "Insulin-like growth factor I and its binding protein 3 in sepsis", Growth Horm IGF Res, 23, pp.98~104 (2013)
- Takala J, "Increased mortality associated with growth hormone treatment in critically ill adults", N Engl J Med, 341, pp.785~792 (1999)
- Donmez R, "The combined effects of glutamine and growth hormone on intestinal anastomosis in the rat intra-abdominal sepsis model", J Surg Res, 182, pp.142~145 (2013)
- Voerman HJ, "Effects of recombinant human growth-hormone in patients with severe sepsis", Ann Surg, 216, pp.648~655 (1992)
- Bjarnason R, "Growth hormone treatment prevents the decrease in insulin-like growth factor I gene expression in patients undergoing abdominal surgery", J Clin Endocrinol Metab, 83, pp.1566~1572 (1998)
- Yue C, "Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone", Inflamm Res, 62, pp.407~415 (2013)
- Jaffa AA, "Induction of renal kallikrein and renin gene expression by insulin and IGF-I in the diabetic rat", Diabetes, 46, pp.2049~2056 (1997)
- Haddad GE, "Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist", Can J Physiol Pharmacol, 81, pp.142~149 (2003)
- Spicer LJ, "Influence of cortisol on insulin- and insulin-like growth factor 1 (IGF-1)-induced steroid production and on IGF-1 receptors in cultured bovine granulosa cells and thecal cells", Endocrine, 9, pp.153~161 (1998)
- Weber MM, "Insulin-like growth factor II (IGF-II) is more potent than IGF-I in stimulating cortisol secretion from cultured bovine adrenocortical cells: interaction with the IGF-I receptor and IGF-binding proteins", Endocrinology, 136, pp.3714~3720 (1995)
- "American-College of Chest Physicians Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis", Crit Care Med, 20, pp.864~874 (1992)
- Dellinger RP, "Surviving Sepsis Campaign:international guidelines for management of severe sepsis and septic shock: 2008", Crit Care Med, 36, pp.296~327 (2008)
- Lin MC, "Down-regulation of insulin-like growth factor I (IGF-I) in the mouse diaphragm during sepsis", Chang Gung Med J, 33, pp.501~508 (2010)
- Heemskerk VH, "Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation", Cytokine Growth Factor Rev, 10, pp.5~14 (1999)
- Dahn MS, "Insulinlike growth factor-I production is inhibited in human sepsis", Arch Surg, 123, pp.1409~1414 (1988)
- Van den Berghe G, "Endocrine changes in critically ill patients", Growth Horm IGF Res, 9(Suppl A), pp.77~81 (1999)
- Ashare A, "Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance", Am J Respir Crit Care Med, 178, pp.149~157 (2008)
- Gianotti L, "Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions", J Endocrinol Invest, 21, pp.115~121 (1998)
- Frayn KN, "Plasma somatomedin activity after injury in man and its relationship to other hormonal and metabolic changes", Clin Endocrinol (Oxf), 20, pp.179~187 (1984)
- Schuetz P, "Circulating levels of GH predict mortality and complement prognostic scores in critically ill medical patients", Eur J Endocrinol, 160, pp.157~163 (2009)
- de Groof F, "Acute stress response in children with meningococcal sepsis: important differences in the growth hormone", insulin-like growth factor I axis between nonsurvivors and survivors, 2002, pp.87, 3118~3124
- Doerschug KC, "Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis", Crit Care, 14, pp.R24~ (2010)
- Salgado DR, "Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach?", Expert Opin Ther Targets, 14, pp.11~20 (2010)
- Volbeda M, "Glucocorticosteroids for sepsis:systematic review with meta-analysis and trial sequential analysis", Intensive Care Med, 41, pp.1220~1234 (2015)
- Kajstura J, "IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress", Diabetes, 50, pp.1414~1424 (2001)